Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab add-on to certolizumab pegol in moderate-to-severe rheumatoid arthritis
2014-003307-30Phase 2Completed
- Sponsor
- UCB
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Bimekizumab add-on arm with Placebo add-on control arm (2 arms). Primary endpoint: Incidence of adverse events. Started Jan 2015; status: completed.
02
Drugs
bimekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-003307-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003307-30.